Spring Bank Pharmaceuticals Presents Study Results for Novel
Anti-Viral Pharmaceuticals from its Small Molecule Nucleic Acid
Hybrid technology platform
Milford, MA – February 2010 – Spring Bank Pharmaceuticals, Inc., a
biopharmaceutical company capitalizing on its proprietary Small Molecule Nucleic Acid
Hybrid technology platform announced today that it will present four (4) posters on it
breakthrough products for the treatment of Hepatitis C and Hepatitis B virus infections at
the 23rd International Conference on Antiviral Research being held in San Francisco, CA,
USA beginning April 25, 2010.
“Presenting at ICAR will be a great opportunity for Spring Bank to showcase some
results from our breakthrough new product, SB 9200 for the treatment of Hepatitis C and
B.” said Doug Jensen, President and CEO of Spring Bank Pharmaceuticals. “SB 9200 is a
totally new class of antiviral therapeutic. Based on our proprietary Small Molecule
Nucleic Acid Hybrid technology platform it works by a novel dual mechanism of action
having both direct antiviral and immune stimulatory activities.”
The posters presentations will be held at the Hyatt Regency Conference Center, San
Francisco on Monday, April 26, 2010 in a session entitled: Hepatitis Viruses Poster
Session 1: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and
Antiviral Methods
About the Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is an IND-stage drug discovery company. Based on our
proprietary platform technology, we are developing a pipeline of products representing a
new class of pharmaceuticals we call small molecule nucleic acid hybrids “SMNH” with
a wide range of applications and multi-billion dollar market potential.
About Hepatitis
Over 350 million people are chronically infected with HBV virus worldwide. The HBV virus is a DNA virus which incorporates into the hepatocyte DNA. Read More >>
Approximately 170 million people worldwide and 4 million in the United States are infected with HCV. HCV infection is one of the most significant public health threats facing Americans.
Read More >>
